Goldman Sachs Group Inc Iovance Biotherapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,390,032 shares of IOVA stock, worth $35.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,390,032
Previous 2,621,784 67.44%
Holding current value
$35.7 Million
Previous $21 Million 96.05%
% of portfolio
0.01%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$7.28 - $11.9 $12.9 Million - $21 Million
1,768,248 Added 67.44%
4,390,032 $41.2 Million
Q2 2024

Aug 13, 2024
SELL
$7.78 - $14.19 $9.03 Million - $16.5 Million
-1,160,779 Reduced 30.69%
2,621,784 $21 Million
Q1 2024

May 15, 2024
BUY
$7.59 - $17.47 $766,612 - $1.76 Million
101,003 Added 2.74%
3,782,563 $56.1 Million
Q4 2023

Feb 13, 2024
SELL
$3.3 - $8.89 $270,857 - $729,673
-82,078 Reduced 2.18%
3,681,560 $29.9 Million
Q3 2023

May 14, 2024
BUY
$4.44 - $8.79 $364,426 - $721,465
82,078 Added 2.23%
3,763,638 $17.1 Million
Q3 2023

Nov 14, 2023
BUY
$4.44 - $8.79 $1.01 Million - $2.01 Million
228,371 Added 6.46%
3,763,638 $17.1 Million
Q2 2023

May 14, 2024
SELL
$5.36 - $9.06 $2.13 Million - $3.6 Million
-397,717 Reduced 10.11%
3,535,267 $24.9 Million
Q2 2023

Aug 14, 2023
SELL
$5.36 - $9.06 $2.13 Million - $3.6 Million
-397,717 Reduced 10.11%
3,535,267 $24.9 Million
Q1 2023

May 14, 2024
BUY
$5.53 - $8.22 $1.6 Million - $2.38 Million
289,919 Added 7.96%
3,932,984 $24 Million
Q1 2023

May 11, 2023
BUY
$5.53 - $8.22 $1.6 Million - $2.38 Million
289,919 Added 7.96%
3,932,984 $24 Million
Q4 2022

May 14, 2024
BUY
$5.62 - $10.0 $3.64 Million - $6.48 Million
648,086 Added 21.64%
3,643,065 $23.3 Million
Q4 2022

Feb 13, 2023
BUY
$5.62 - $10.0 $3.64 Million - $6.48 Million
648,086 Added 21.64%
3,643,065 $23.3 Million
Q3 2022

May 14, 2024
BUY
$9.53 - $13.11 $9.94 Million - $13.7 Million
1,042,633 Added 53.4%
2,994,979 $28.7 Million
Q3 2022

Nov 10, 2022
BUY
$9.53 - $13.11 $9.94 Million - $13.7 Million
1,042,633 Added 53.4%
2,994,979 $28.7 Million
Q2 2022

May 14, 2024
SELL
$6.38 - $18.33 $11 Million - $31.7 Million
-1,729,214 Reduced 46.97%
1,952,346 $21.6 Million
Q2 2022

Aug 15, 2022
BUY
$6.38 - $18.33 $8.79 Million - $25.3 Million
1,377,975 Added 239.91%
1,952,346 $21.6 Million
Q1 2022

May 16, 2022
SELL
$12.38 - $19.1 $10.8 Million - $16.7 Million
-875,433 Reduced 60.38%
574,371 $9.56 Million
Q4 2021

Feb 14, 2022
BUY
$16.55 - $27.63 $3.22 Million - $5.38 Million
194,704 Added 15.51%
1,449,804 $27.7 Million
Q3 2021

Nov 10, 2021
BUY
$20.35 - $26.63 $25.5 Million - $33.4 Million
1,255,100 New
1,255,100 $31 Million

Others Institutions Holding IOVA

# of Institutions
313
Shares Held
241M
Call Options Held
3.77M
Put Options Held
1.7M
View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

IOVA Quotes by TradingView
  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.28B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email